cyclophosphamide + epirubicin + paclitaxel + sorafenib

This is a combination regimen consisting of four distinct anticancer agents: - Cyclophosphamide, an alkylating agent that interferes with DNA replication and RNA transcription, leading to cell death. - Epirubicin, an anthracycline antibiotic that inhibits topoisomerase II and intercalates into DNA, disrupting DNA synthesis and repair. - Paclitaxel, a taxane that stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division. - Sorafenib, a multikinase inhibitor targeting several tyrosine protein kinases including RAF kinases (CRAF, BRAF), vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), FLT3, c-KIT and RET. It inhibits tumor cell proliferation and angiogenesis. This combination is not a standard or widely approved regimen but may be investigated in clinical trials for advanced or refractory cancers. Each component has established use in oncology—cyclophosphamide and epirubicin are commonly used together for breast cancer; paclitaxel is used in various solid tumors; sorafenib is primarily indicated for hepatocellular carcinoma and renal cell carcinoma.